writer：Xinge Zhang*, Yanxia Wang, Chao Zheng, Chaoxing Li*.
keywords：nasal delivery
source：期刊
specific source：European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 76-84.
Issue time：2012年

The aim of this study was to explore the potential of the mucoadhesive and enzyme-inhibitory phenylboronic acid-functionalized glycopolymeric nanoparticles as carriers for the nasal delivery of biomacromolecules. The glycopolymers were prepared by the random copolymerization of 3-acrylamidophenylboronic acid and N-acetyl glucosamine. Insulin, as a model, was encapsulated within self-assembled glypolymeric nanoparticles. Nanoparticle size, insulin loading, and insulin release were characterized. In vitro cytotoxicity experiment showed the glycopolymers were cytocompatible (≥ 80% cell viability). Adhesiveness was determined from the absorption amount of mucin, reaching up to 1180 μg/mL. Moreover, the results obtained from in vivo administration of insulin-loaded p(AAPBA-r-MAGA) nanoparticles to rats evidenced that the nanoparticles enhanced insulin absorption across the nasal mucosal barrier and did not induce irritation of nasal mucosa. Thus, insulin-loaded nanoparticles were able to significantly decrease plasma glucose levels (more than 35% reduction). These results suggest that p(AAPBA-r-MAGA) nanoparticles have potential application for the nasal delivery of biomacromolecules.